Novartis has signed an agreement contracting Cryoport for an initial three-year term for cryogenic logistics support of CTL019/CD19 CAR-T cell therapy. In March, Novartis’ BLA for CTL019 was accepted by the FDA and was also granted priority review.    Cryoport will support Novartis’ expanding cryogenic logistics requirements, including the use of its Cryoport Express shippers, SmartPak II Condition Monitoring System, Cryoportal Logistics Management Platform, which includes chain-of-condi...